8 completed, 2 not yet recruiting, 1 active not recruiting, 1 recruiting. 14 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 8, Not yet recruiting 2, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Completed 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Drug Resistant Epilepsy: new trials by email Literature Review of Drug Resistant Epilepsy trials Research Report on Drug Resistant Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042 NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2) - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 8 | 2025-09-29 | 2026-04-03 |
| Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies Ketogenic diet - Developmental and Epileptic Encephalopathies, Epileptic Spasms | Phase 1 | Terminated | Heather Olson | 1 | 2025-08-11 | 2026-10-14 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 iQ-007, Placebo - Drug Resistant Epilepsy, Focal Seizure | Phase 1 | Active not recruiting | iQure Australia Pty Ltd | 72 | 2025-04-08 | 2025-12-29 |
| Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Drug Resistant Epilepsy Single Center, Non-randomized, Phase I Clinical Trial Secretome - Epilepsy, Drugs Resistant Epilepsy | Phase 1 | Not yet recruiting | Baermed | 54 | 2024-12-01 | 2024-10-15 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy NaviFUS System - Drug Resistant Epilepsy, Epilepsy | Phase 1 / Phase 2 | Recruiting | NaviFUS Corporation | 8 | 2024-09-13 | 2026-09-15 |
| Lentiviral Gene Therapy for Epilepsy lentiviral gene therapy - Drug Resistant Epilepsy | Phase 1 / Phase 2 | Not yet recruiting | University College, London | 10 | 2024-09-01 | 2023-05-15 |
| Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy Leucine-Enriched Essential Amino Acid powder - Refractory Epilepsy, Drug Resistant Epilepsy | Phase 1 | Completed | Elizabeth Anne Thiele | 4 | 2024-05-10 | 2026-05-22 |
| Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects NPT 2042 (bumetanide analog) or Matching Placebo - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 50 | 2022-10-20 | 2023-04-04 |
| Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy methylprednisolone sodium succinate, Placebo - Intractable Epilepsy, Convulsive Seizures | Phase 1 / Phase 2 | Unknown | Louisiana State University Health Sciences Center in New Orleans | 10 | 2020-02-03 | 2020-02-07 |
| ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE) ABI-009 - Epilepsy Intractable | Phase 1 | Completed | Seattle Children's Hospital | 14 | 2018-07-31 | 2023-05-06 |
| Intrathecal Autologous ADRC Treatment of Autoimmune Refractory Epilepsy ADRC transplantation in autoimmune refractory epilepsy - Refractory Epilepsy | Phase 1 | Completed | Mossakowski Medical Research Centre Polish Academy of Sciences | 6 | 2015-11-15 | 2020-04-15 |
| Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome Cannabidiol - Sturge-Weber Syndrome | Phase 1 / Phase 2 | Completed | Anne Comi, MD | 5 | 2014-12-01 | 2022-03-02 |
| Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy Cannabidiol - Epilepsy | Phase 1 | Completed | University of Utah | 26 | 2014-09-18 | 2020-01-27 |
| Thalidomide Low Threshold in Epilepsy 3-phthalimidoglutarimide (Thalidomide) - Refractory Epilepsy | Phase 1 / Phase 2 | Completed | National Institute of Neurology and Neurosurgery, Mexico | 7 | 2006-06-01 | 2010-02-18 |
Epilepsy (6) · Seizures (5) · Alzheimer Disease (2) · Central Nervous System Diseases (2) · Epilepsies, Myoclonic (1) · Spasms, Infantile (1) · Sturge-Weber Syndrome (1)
Brain Diseases (14) · Nervous System Diseases (14) · Central Nervous System Diseases (12) · Epilepsy (8) · Neurologic Manifestations (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Dementia (2) · Epilepsy, Generalized (2) · Epileptic Syndromes (2) · Mental Disorders (2) · Neurocognitive Disorders (2) · Neurodegenerative Diseases (2) · Tauopathies (2) · Angiomatosis (1)
Cannabidiol (2) · Bumetanide (1) · Diet, Ketogenic (1) · Methylprednisolone Hemisuccinate (1) · Secretome (1) · Thalidomide (1)
NeuroPro Therapeutics, Inc. (2) · Anne Comi, MD (1) · Baermed (1) · Elizabeth Anne Thiele (1) · Heather Olson (1) · Louisiana State University Health Sciences Center in New Orleans (1) · Mossakowski Medical Research Centre Polish Academy of Sciences (1) · National Institute of Neurology and Neurosurgery, Mexico (1) · NaviFUS Corporation (1) · Seattle Children's Hospital (1) · University College, London (1) · University of Utah (1) · iQure Australia Pty Ltd (1)
United States (9) · Australia (1) · Indonesia (1)
Anne M Comi, MD (1) · Colin VanOrman, MD (1) · Dorota Antczak-Marach, M.D. (1) · Elizabeth Thiele, MD, PhD (1) · Ewa Sawicka, Prof. (1) · Francis Filloux, MD (1) · Henk de Wilde (1) · Jason Hauptman, MD, PhD (1) · Jeremy Toler, MD (1) · Julio Sotelo, MD (1) · Mathew Sweeney, MD (1)